Department of Molecular Toxicology, Faculty of Pharmaceutical Sciences, Toho University.
Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka.
Biol Pharm Bull. 2021;44(4):571-578. doi: 10.1248/bpb.b20-00961.
We had previously reported that treatment with the aryl hydrocarbon receptor (AHR) agonist β-naphthoflavone (βNF) suppressed mammosphere formation derived from cancer stem cells in human breast cancer MCF-7 cells (Cancer Lett., 317, 2012, Zhao et al.). Here, using several AHR agonists, we have investigated the association of this suppression with the classical ability to induce AHR-mediated gene transcription in the xenobiotic response element (XRE). The mammosphere formation assays were performed using wild-type and AHR-knockout MCF-7 cells in the presence of AHR agonists including 3-methylcholanthrene (3MC), benzo[a]pyrene (BaP), 7,12-dimethylbenz[a]anthracene (DMBA), 6-formylindolo[3,2-b]carbazole (FICZ), indirubin, indole-3-carbinol (I3C), indole-3-acetic acid (IAA), and kynurenine (KYN), followed by the XRE-reporter gene assays of the agonists. We showed that treatments with 3MC, BaP, and DMBA strongly suppressed mammosphere formation of the stem cells in an AHR-dependent manner, while other agonists showed weaker suppression. In reporter gene assays, the strength or duration of AHR/XRE-mediated gene transcription was found to be dependent on the agonist. Although strong transcriptional activation was observed with 3MC, FICZ, indirubin, I3C, IAA, or KYN after 6 h of treatment, only weak activation was seen with BaP or DMBA. While transcriptional activation was sustained or increased at 24 h with 3MC, BaP, or DMBA, appreciable reduction was observed with the other agonists. In conclusions, the results demonstrated that the suppressive effects of AHR agonists on mammosphere formation do not necessarily correlate with their abilities to induce AHR-mediated gene transcription. Hence, different AHR functions may be differentially induced in an agonist-dependent manner.
我们之前曾报道过,芳基烃受体(AHR)激动剂β-萘黄酮(βNF)的治疗抑制了人乳腺癌 MCF-7 细胞中源自癌症干细胞的乳腺球形成(Cancer Lett.,317,2012,Zhao 等人)。在这里,我们使用几种 AHR 激动剂研究了这种抑制作用与经典的诱导外源性反应元件(XRE)中 AHR 介导的基因转录的能力之间的关联。在存在 AHR 激动剂(包括 3-甲基胆蒽(3MC)、苯并[a]芘(BaP)、7,12-二甲基苯并[a]蒽(DMBA)、6-甲氧基吲哚并[3,2-b]咔唑(FICZ)、靛玉红、吲哚-3-甲醇(I3C)、吲哚-3-乙酸(IAA)和犬尿氨酸(KYN)的情况下,使用野生型和 AHR 敲除 MCF-7 细胞进行乳腺球形成测定,随后进行激动剂的 XRE-报告基因测定。我们表明,3MC、BaP 和 DMBA 的处理以 AHR 依赖性方式强烈抑制了干细胞的乳腺球形成,而其他激动剂的抑制作用较弱。在报告基因测定中,发现 AHR/XRE 介导的基因转录的强度或持续时间取决于激动剂。尽管在用 3MC、FICZ、靛玉红、I3C、IAA 或 KYN 处理 6 小时后观察到强烈的转录激活,但在用 BaP 或 DMBA 处理时仅观察到弱激活。虽然在用 3MC、BaP 或 DMBA 处理 24 小时时,转录激活持续或增加,但用其他激动剂观察到明显减少。总之,结果表明 AHR 激动剂对乳腺球形成的抑制作用不一定与其诱导 AHR 介导的基因转录的能力相关。因此,不同的 AHR 功能可能以激动剂依赖性方式差异诱导。